Gland Pharma [GLAND] vs Syngene [SYNGENE] Detailed Comparison
Gland Pharma
NSE
Loading...
Syngene
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gland Pharma wins in 13 metrics, Syngene wins in 7 metrics, with 0 ties. Gland Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gland Pharma | Syngene | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 47.39 | 54.29 | Gland Pharma |
| Price-to-Book Ratio | 3.62 | 5.71 | Gland Pharma |
| Debt-to-Equity Ratio | 3.43 | 12.23 | Gland Pharma |
| PEG Ratio | 30.92 | 39.82 | Gland Pharma |
| EV/EBITDA | 21.66 | 25.08 | Gland Pharma |
| Profit Margin (TTM) | 12.44% | 13.62% | Syngene |
| Operating Margin (TTM) | 17.67% | 24.07% | Syngene |
| EBITDA Margin (TTM) | 17.67% | 24.07% | Syngene |
| Return on Equity | 7.82% | 11.05% | Syngene |
| Return on Assets (TTM) | 5.09% | 5.93% | Syngene |
| Free Cash Flow (TTM) | $5.21B | $3.98B | Gland Pharma |
| Dividend Yield | 1.15% | 0.39% | Gland Pharma |
| 1-Year Return | 0.97% | -13.22% | Gland Pharma |
| Price-to-Sales Ratio (TTM) | 5.90 | 7.40 | Gland Pharma |
| Enterprise Value | $274.80B | $248.62B | Gland Pharma |
| EV/Revenue Ratio | 4.89 | 6.83 | Gland Pharma |
| Gross Profit Margin (TTM) | 65.76% | 76.92% | Syngene |
| Revenue per Share (TTM) | $341 | $91 | Gland Pharma |
| Earnings per Share (Diluted) | $42.41 | $12.36 | Gland Pharma |
| Beta (Stock Volatility) | 0.32 | 0.15 | Syngene |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Gland Pharma vs Syngene Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gland Pharma | 3.88% | 3.48% | 12.46% | 35.21% | 20.09% | 8.38% |
| Syngene | 0.70% | 3.15% | 6.28% | -8.11% | -18.37% | -23.12% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gland Pharma | 0.97% | -11.86% | 10.47% | 10.47% | 10.47% | 10.47% |
| Syngene | -13.22% | 19.61% | 39.34% | 324.54% | 324.54% | 324.54% |
Performance & Financial Health Analysis: Gland Pharma vs Syngene
| Metric | GLAND | SYNGENE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹331.13B | ₹269.61B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 677,810 | 1,130,751 |
| 90 Day Avg. Volume | 390,650 | 917,484 |
| Last Close | ₹2,038.00 | ₹680.75 |
| 52 Week Range | ₹1,277.80 - ₹2,220.95 | ₹599.55 - ₹960.60 |
| % from 52W High | -8.24% | -29.13% |
| All-Time High | ₹4,350.00 (Aug 09, 2021) | ₹960.60 (Dec 02, 2024) |
| % from All-Time High | -53.15% | -29.13% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.07% | 0.11% |
| Quarterly Earnings Growth | -0.03% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.14% |
| Operating Margin (TTM) | 0.18% | 0.24% |
| Return on Equity (TTM) | 0.08% | 0.11% |
| Debt to Equity (MRQ) | 3.43 | 12.23 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹555.30 | ₹117.59 |
| Cash per Share (MRQ) | ₹185.08 | ₹34.77 |
| Operating Cash Flow (TTM) | ₹9.15B | ₹11.68B |
| Levered Free Cash Flow (TTM) | ₹6.79B | ₹2.16B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.15% | 0.39% |
| Last 12-Month Dividend | ₹20.00 | ₹2.50 |
Valuation & Enterprise Metrics Analysis: Gland Pharma vs Syngene
| Metric | GLAND | SYNGENE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 47.39 | 54.29 |
| Forward P/E | 30.92 | 39.82 |
| PEG Ratio | 30.92 | 39.82 |
| Price to Sales (TTM) | 5.90 | 7.40 |
| Price to Book (MRQ) | 3.62 | 5.71 |
| Market Capitalization | ||
| Market Capitalization | ₹331.13B | ₹269.61B |
| Enterprise Value | ₹274.80B | ₹248.62B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.89 | 6.83 |
| Enterprise to EBITDA | 21.66 | 25.08 |
| Risk & Other Metrics | ||
| Beta | 0.32 | 0.15 |
| Book Value per Share (MRQ) | ₹555.30 | ₹117.59 |
Financial Statements Comparison: Gland Pharma vs Syngene
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GLAND | SYNGENE |
|---|---|---|
| Revenue/Sales | ₹14.25B | ₹10.18B |
| Cost of Goods Sold | ₹4.88B | ₹2.35B |
| Gross Profit | ₹9.37B | ₹7.83B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹2.52B | ₹2.42B |
| EBITDA | ₹3.92B | ₹3.63B |
| Pre-Tax Income | ₹2.88B | ₹2.41B |
| Income Tax | ₹1.02B | ₹572.00M |
| Net Income (Profit) | ₹1.87B | ₹1.83B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GLAND | SYNGENE |
|---|---|---|
| Cash & Equivalents | ₹25.56B | ₹3.67B |
| Total Current Assets | ₹67.83B | ₹22.87B |
| Total Current Liabilities | ₹15.65B | ₹13.96B |
| Long-Term Debt | ₹1.07B | ₹4.09B |
| Total Shareholders Equity | ₹91.51B | ₹47.27B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹37.93B | ₹27.42B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GLAND | SYNGENE |
|---|---|---|
| Operating Cash Flow | ₹2.07B | ₹2.17B |
| Capital Expenditures | ₹-659.37M | ₹-680.00M |
| Free Cash Flow | ₹126.04M | ₹1.27B |
| Debt Repayment | N/A | ₹0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GLAND | SYNGENE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 677,810 | 1,130,751 |
| Average Daily Volume (90 Day) | 390,650 | 917,484 |
| Shares Outstanding | 164.76M | 401.37M |
| Float Shares | 73.19M | 177.83M |
| % Held by Insiders | 0.52% | 0.53% |
| % Held by Institutions | 0.34% | 0.32% |
Dividend Analysis & Yield Comparison: Gland Pharma vs Syngene
| Metric | GLAND | SYNGENE |
|---|---|---|
| Last 12-Month Dividend | ₹20.00 | ₹2.50 |
| Last 12-Month Dividend Yield | 1.15% | 0.39% |
| 3-Year Avg Annual Dividend | ₹6.67 | ₹1.25 |
| 3-Year Avg Dividend Yield | 1.07% | 0.14% |
| 3-Year Total Dividends | ₹20.00 | ₹3.75 |
| Ex-Dividend Date | Aug 16, 2024 | Jun 27, 2025 |